Fluticasone furoate/vilanterol clinical studies
Pro Research Analysisby 
Searched over 200M research papers
Fluticasone Furoate/Vilanterol Clinical Studies: Efficacy and Safety in Asthma and COPD
Efficacy in Asthma: Pulmonary Function and Asthma Control
Clinical studies show that fluticasone furoate/vilanterol (FF/VI), a once-daily inhaled corticosteroid (ICS) and long-acting β2-agonist (LABA) combination, significantly improves lung function in adolescents and adults with symptomatic asthma. Compared to ICS monotherapy or twice-daily ICS-LABA combinations, FF/VI leads to greater increases in forced expiratory volume in 1 second (FEV1) and peak expiratory flow (PEF), and reduces the rate of severe asthma exacerbations. Both available doses (100/25 μg and 200/25 μg) show similar efficacy, though higher doses may have a trend toward increased cardiac events 110.
In real-world clinical practice, FF/VI improves asthma control more than optimized usual care, with a higher proportion of patients achieving clinically meaningful improvements in Asthma Control Test (ACT) scores. These benefits are sustained over time, and the risk of serious adverse events, including pneumonia, is not increased compared to usual care . Additionally, once-daily FF/VI delivered via pressurized metered-dose inhaler (pMDI) is non-inferior to twice-daily formoterol/fluticasone propionate in persistent asthma, with similar improvements in FEV1 and no serious adverse events reported .
Efficacy in COPD: Lung Function, Exacerbations, and Survival
In patients with moderate-to-severe chronic obstructive pulmonary disease (COPD), FF/VI provides rapid and sustained bronchodilation, significantly improving lung function compared to placebo and to the individual components alone. Both 100/25 μg and 50/25 μg doses are effective, and the combination is generally well tolerated 27.
FF/VI also reduces the rate of moderate and severe COPD exacerbations compared to vilanterol alone, though this benefit comes with an increased risk of pneumonia. The combination is more effective than vilanterol alone in preventing exacerbations, but pneumonia and fractures are reported more frequently with FF/VI 67.
In patients with moderate COPD and heightened cardiovascular risk, FF/VI does not reduce all-cause mortality or cardiovascular events compared to placebo. However, it does reduce the rate of FEV1 decline and the frequency of moderate and severe exacerbations, with a safety profile similar to placebo regarding pneumonia and cardiac events 49.
Real-World Effectiveness and Adherence
Effectiveness studies in routine clinical practice settings, such as the INTREPID study, are ongoing to compare once-daily FF/umeclidinium/vilanterol (a triple therapy including FF/VI) delivered by a single inhaler to multiple-inhaler triple therapies. These studies aim to provide evidence on health status improvements, lung function, and inhaler errors in real-world COPD management .
The once-daily dosing of FF/VI is highlighted as a potential advantage for improving treatment adherence compared to twice-daily regimens, which may be particularly beneficial for patients who struggle with complex inhaler schedules 78.
Safety and Tolerability
Across studies, FF/VI is generally well tolerated in both asthma and COPD populations. The most common adverse events are oral/oropharyngeal candidiasis, dysphonia, and cough. The risk of pneumonia is increased with long-term use, especially in COPD, but the overall incidence of serious adverse events is similar to comparator treatments 6710.
Conclusion
Fluticasone furoate/vilanterol is an effective, generally well-tolerated, once-daily ICS/LABA combination for the treatment of asthma and COPD. It improves lung function, reduces exacerbations, and offers the convenience of once-daily dosing, which may enhance adherence. However, clinicians should be aware of the increased risk of pneumonia in COPD patients and monitor for potential cardiac events, especially at higher doses. Ongoing real-world studies will further clarify its effectiveness in routine clinical practice.
Sources and full results
Most relevant research papers on this topic
Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
Fluticasone furoate-vilanterol combination improves pulmonary function and reduces asthma exacerbations, but differences may not be clinically significant.
DOI